Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG ...
-
Upload
thomasine-wells -
Category
Documents
-
view
219 -
download
1
Transcript of Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG ...
![Page 1: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/1.jpg)
Yael MoussadjiAug 21, 2008
![Page 2: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/2.jpg)
Diagnosis of ACS in the ED Risk Stratification
Cardiac markers ECG Risk Scores
Management UA/NSTEMI STEMI
Complications
![Page 3: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/3.jpg)
![Page 4: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/4.jpg)
![Page 5: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/5.jpg)
54 y/o male with 2 hours of exertional retrosternal burning CP
No previous episodes of pain Feels slightly SOB VSS, exam normal ECG non-specific, TnT neg You ask CCU to see because you are
concerned re the possibility of an ACS (UA)
The CCU res asks, does he have any risk factors?
![Page 6: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/6.jpg)
Are cardiac risk factors useful in evaluating the risk of ACS?
![Page 7: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/7.jpg)
Post-hoc analysis of 10,806 ED visits for ACS using the i*trACS registry for ED visits for ACS
ACS defined as need for 30-day revascularization (PTCA or CABG), or death or AMI with positive cardiac enzymes at hospitalization
Cardiac RF were diabetes, HTN, dyslipidemia, smoking, + family history of CAD; cardiac RF burden defined as number of RF present
Analysis stratified by age; <40, 40-65, >65
![Page 8: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/8.jpg)
![Page 9: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/9.jpg)
![Page 10: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/10.jpg)
In patients over 40, cardiac risk factor burden is of limited clinical value in the diagnosis of ACS
In patients under 40, cardiac RF useful if there are none (-LR 0.17) or if there are 4 or more (+LR 7.39)
![Page 11: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/11.jpg)
61 y/o female with 45 minutes of sharp left sided pleuritic chest pain
Feels nauseated, slightly diaphoretic Pain is radiating to her left shoulder No PMHx, no DVT/PE risk factors Cardiac Risk factors: Who cares? Vital signs are normal, ECG nonspecific,
enzymes pending
![Page 12: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/12.jpg)
How useful are clinical features in the diagnosis of acute, undifferentiated chest
pain?
![Page 13: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/13.jpg)
Measured the predictive value and diagnostic performance of clinical features used to diagnose ACS in undifferentiated CP
Clinical features were prospectively recorded on a standard form for 893 patients presenting to the ED; 3.8% had an MI and 9.1% had ACS
Six month follow-up for adverse events Tested the power of each feature to predict
AMI (WHO criteria) and ACS (cardiac testing, AMI, death, or revascularization within 6 months
![Page 14: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/14.jpg)
![Page 15: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/15.jpg)
![Page 16: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/16.jpg)
Features useful in the diagnosis of AMI were exertional pain (LR 2.35), pain radiating to the shoulder or both arms (LR 4.07), and chest wall tenderness (LR 0.3)
Features useful in the diagnosis of ACS were exertional pain (LR 2.06), pain radiating to the shoulder, left arm, or both arms (LR 1.62)
Location, quality, and presence of N/V or diaphoresis were not predictive
![Page 17: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/17.jpg)
A 57 y/o male with no PMHx presents to the ED with CP
Pain has been intermittent for 2 weeks, and is described as pleuritic and exertional; occational nausea is noted
Physical exam is unremarkable Patient’s pain resolved spontaneously
prior to medical therapy, and he is pain free when you see him
![Page 18: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/18.jpg)
![Page 19: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/19.jpg)
Enzymes were negative Patient was discharged home with
instructions to return if worse, and referral to C-era.
24 hours later, the patient returns to emerg with ongoing chest discomfort, nausea, and diaphoresis
![Page 20: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/20.jpg)
![Page 21: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/21.jpg)
What is the predictive and prognostic value of the ECG in patients with ACS?
![Page 22: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/22.jpg)
Non-specific ST and T wave changes ST segment depression or elevation of < 1mm
with or without an abnormal T wave T wave may have altered morphology and/or
blunted, flattened, or biphasic configuration without inversion or hyperacuity
Normal Absence of NSSTTW, AV block, intraventricular
conduction delay, repolarization changes, and rhythms other than NSR
![Page 23: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/23.jpg)
In a study of adult CP patients in the ED, 1% of patients with a normal ECG had a final diagnosis of AMI, and 4% had a final diagnosis of UA
In another study, of patients with classic angina on history and a normal ECG, 3% had a final diagnosis of AMI
3-4% of patients with AMI and over 20% of patients with an ACS (NSTEMI/UA) have NSSTTW findings
Therefore, of all patients with ACS, one fifth will show a normal or non-specific ECG in the ED
![Page 24: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/24.jpg)
![Page 25: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/25.jpg)
![Page 26: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/26.jpg)
Of 202 chest pain patients presenting to the ED with STE, 15% had an AMI
LVH was the most common cause of STE (25%), followed by LBBB (15%) and AMI (15%)
12% had BER, 5% had RBBB, and 5% had nonspecific BBB
Other less common diagnoses were LVA, pericarditis, and paced rhythm
![Page 27: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/27.jpg)
A retrospective analysis of GUSTO-IIb trial Over 12,000 patients who had ACS confirmed on
ECG 22% had T wave inversion, 28% had STE, 35% had
STD, and 15% had a combination of the above 30 day incidence of death or MI was 5.5% in those
with T wave inversions, 9.4% in those with STE, 10.5% in those with STD, and 12.4% in those with a STE + STD
In another study of 205 consecutive patients with UA/NSTEMI, STE of > 0.5mm in aVR was found to be a strong predictor of 30-day mortality, even in patients with low TIMI risk scores
![Page 28: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/28.jpg)
T-wave inversion
ST
ST
P 0.001
CM Gibson 2002
![Page 29: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/29.jpg)
50% of patients with AMI will have a clearly diagnostic ECG at presentation (STE or STD)
ST segment elevation identifies those who benefit from reperfusion therapy (lytics)
Mortality increases with the number of leads showing STE
Other important predictors of mortality include LBBB and anterior location
Reciprocal changes are seen in 70% of inferior and 30% of anterior MIs, which demonstrates over 90% specificity and PPV for AMI
RV infarcts complicate 40% of inferior AMIs
![Page 30: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/30.jpg)
![Page 31: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/31.jpg)
![Page 32: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/32.jpg)
![Page 33: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/33.jpg)
So, if risk factors, clinical features, and ECG’s are not always helpful, how many patient’s with ACS are missed, and what
are their characteristics?
![Page 34: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/34.jpg)
Analyzed clinical data from a multicentre prospective trial of over 10,000 patients with chest pain suggestive of ACS
17% ultimately met the criteria for ACS (8% had AMI and 9% had UA)
2.1% of those with AMI and 2.3% of those with UA were mistakenly discharged from the ED
![Page 35: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/35.jpg)
Acute ischemia Women <55 Non-white SOB as chief
symptom Normal or non-
diagnostic ECG AMI
Non-white Normal or non-
diagnostic ECG
![Page 36: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/36.jpg)
Percentage of patients who get discharged home is low, but discharge of these patients may be associated with increased mortality
Failure to make a diagnosis is related to race, gender, and lack of typical features on ECG
![Page 37: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/37.jpg)
83 y/o male with known renal insufficiency, baseline Cr 150
Presents with vague intermittent CP of 2 days duration, no associated symptoms
PMhx significant for HTN, previous MI and PCTA 10 years ago
ECG non-diagnostic (no acute changes from baseline)
TnT 0.11 CCU res says “it’s elevated because of his
renal failure”
![Page 38: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/38.jpg)
Can you diagnose ACS based on an elevated TnT in a patient with renal
failure?
![Page 39: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/39.jpg)
Analyzed outcomes in over 7000 patients enrolled in the GUSTO IV trial
Assessed baseline TnT level (considered abnormal if >0.1 ng/mL) and Cr clearance
Primary end point was death or MI at 30 days
An elevated TnT level was predictive of death of MI, even among patients with a Cr clearance in the lowest quartile
Cardiac troponin is predictive of short term prognosis in patients with ACS regardless of their level of Cr clearance
![Page 40: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/40.jpg)
![Page 41: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/41.jpg)
Due to near absolute specificity for myocardial tissue and high sensitivity for microscopic zones of myocardial necrosis, cardiac troponins are the preferred biomarker for diagnosing MI
Onset 3-6 hours Peak 12-18 hours Elevated for 5-7 days
Time from onset of symptoms
Approximate sensitivity
6 hours 60%
8 hours 80%
10 hours 90%
![Page 42: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/42.jpg)
Examined the TnT, CK-MB, and ECG abnormalities for risk stratification in patients with ACS within 12 hours on onset of symptoms
Use logistic regression to predict outcome Mortality was significantly higher in the group
with Tn >0.1 ng/mL (ARR 8%) TnT was the variable most strongly related to 30
day mortality, followed by ECG category and the CK-MB level
TnT is a powerful independent predictor of mortality in patients who present with ACS
![Page 43: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/43.jpg)
Prospectively examined 733 patients with acute CP < 12 hours without STE; Tn was measured at least twice on arrival and 4-6 hours later so that one sample was taken at least 6 hours after the onset of pain
TnT was positive in 16% of patients, and 94% of patients who eventually evolved into an AMI
Among patients with UA, TnT was positive in 20%
TnT was a strong independent predictor of cardiac events
The event rate for patients with negative Tn T was 1.1%
![Page 44: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/44.jpg)
![Page 45: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/45.jpg)
2 questions What is the likelihood that the presenting
symptoms represent ACS? What is the likelihood of adverse outcome
Risk stratification process is challenging given then presence of risk factors is an unreliable determinant of ACS, and the ECG and Tn are not very sensitive for UA
2007 ACC/AHA Update to the guidelings for UA/NSTEMI are helpful
![Page 46: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/46.jpg)
![Page 47: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/47.jpg)
![Page 48: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/48.jpg)
2002 Guidelines state that tools such as the TIMI Risk Score can be helpful adjuncts
Since 2002, data from a unselected ED chest pain population have validated its utility
Other recommended tools include the GRACE (Global Registry of Acute Coronary Events) Risk Score and the PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) risk model
A study comparing the 3 showed good predictive accuracy for death at 1 year and MI
However, these tools were developed using population based models and may not be reliable for individual patients; they do not replace clinical judgement
![Page 49: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/49.jpg)
Two phase 3 international, randomized, double-blinded trials (TIMI 11B, ESSENCE)
A total of 1957 with UA/NSTMEI who were assigned to receive UFH in TIMI 11B(test cohort)
3 validation cohorts were the UFH group in ESSENCE and both enoxaparin groups (total of over 5000 patients)
Risk score was derived from test cohort using multivariate logistic regression, assinging a value of 1 when risk factor present, and 0 when absent
Outcomes were at least 1 component of the primary end point (mortality, MI, urgent revascularization)
![Page 50: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/50.jpg)
TIMI Risk Score Age > or = 65 3 or more risk
factors for CAD Prior stenosis of 50%
or more ST segment
deviation at presentation
At least 2 anginal events in 24 hours
Use of ASA in prior 7 days
Elevated serum cardiac markers
![Page 51: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/51.jpg)
![Page 52: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/52.jpg)
![Page 53: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/53.jpg)
ED based prospective observational cohort study in 3929 adult chest pain patients
TIMI risk scores determined at presentation; composite outcome of death, MI, revascularization within 30 days
TIMI risk score successfully stratified an unselected cohort of CP patients with respect to 30 day outcomes, with a range of 2.1% for a score of 0 to 100% for a score of 7
Highest correlated indicator for adverse outcome was positive cardiac biomarker at admission
![Page 54: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/54.jpg)
Prospective observational cohort study evaluating the utility of the TIMI risk score in a broad ED CP population of 1481 patients
30 day outcomes were death, MI, revascularization
Incidence of composite outcome was: TIMI 0, 1.7%; TIMI 1, 8.2%; TIMI 3, 8.6%; TIMI 4, 24.6%; TIMI 5, 37.5%; TIMI 6, 33.3%
This relationship was highly significant Failed to stratify patients into discrete groups Patients with a score of 0 still have an incidence
of adverse events of 1.7%
![Page 55: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/55.jpg)
![Page 56: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/56.jpg)
2007 Guidelines make the following recommendations Nondiagnostic ECGs should be repeated every
15-30 minutes in patients with symptoms and a high clinical suspicion of ACS
Cardiac troponins are considered the preferred biomarker and should be repeated at 8-12 hours if negative at 6 hours
Algorithms and models may be useful in standardizing the approach, but should not replace clinical judgement
![Page 57: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/57.jpg)
54 y/o female, arrives to the ED with 2 hours of exertional CP radiating to the Rt shoulder
No previous cardiac history, only risk factors if + family history
ECG demonstrates STD inferiorly Initial TnT comes back at 0.9 ng/mL The nurses have given ASA and nitro, and
ask you if you want to give plavix?
![Page 58: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/58.jpg)
Should all patients with ACS (UA/NSTEMI/STEMI) get plavix?
![Page 59: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/59.jpg)
ASA Multiple RCTs have demonstrated the benefits
of ASA ISIS-2 showed conclusively the efficacy of ASA
alone for the treatment of an MI, with an ARR for 35 day mortality of 2.4% (RRR 23%).
When combined with streptokinase, the ARR in mortality was 5.2% (RRR 42%)
There is a benefit if given early
![Page 60: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/60.jpg)
![Page 61: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/61.jpg)
Thienopyridine derivative that inhibits ADP action on platelet receptors, blocking platelet activation and aggregation
600 mg achieves irreversible platelet inhibition in 2 hours, 300 mg by 4-6 hours, and 75 mg by 3-4 days
CURE, CAPRIE, and COMMIT Trials have evaluated the use of clopidogrel in ACS
CAPRIE studied clopidogrel vs ASA in over 19,000 patienst with ACS; patients on plavix had a 9% RRR (NNT 196) over ASA, and may be used in lieu of ASA if needed
![Page 62: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/62.jpg)
CURE trial Over 12,000 patients randomized to receive
plavix (300 mg loading dose + 75 mg daily) and ASA or ASA alone for a mean of 9 months
Patients were high risk for ACS/NSTEMI Primary composite outcome of death from
CV cause, MI, stroke Results: 20% RRR (2.1% ARR = NNT 48) for
combined primary end point Higher risk of major (non-fatal) bleeding with
plavix (NNH 100)
![Page 63: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/63.jpg)
Benefit was seen within 24 hours (dose early)
Oral loading dose rapidly effective
![Page 64: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/64.jpg)
A subset of the CURE trial of patients with NSTEMI undergoing PCI
Benefit of early treatment with plavix in patients undergoing PCI
ARR 3.8%, NNT 26 of composite end point (CV death, MI, need for revascularization)
![Page 65: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/65.jpg)
RCT of over 45,000 patients seen within 24 hours of suspected MI (LBBB, STE, STD)
Randomized to plavix 75 mg daily or placebo (all patients received ASA); no loading dose
Primary composite outcome of death, MI, stroke
ARR of 0.9% and NNT 111 for composite end point
Small but significant risk of minor bleeding Benefits are independent of other standard
treatments (lytics) Plavix in the ED prevents about 10 deaths,
reinfarctions or strokes for every 1000 patients treated
![Page 66: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/66.jpg)
![Page 67: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/67.jpg)
Studies have demonstrated a benefit to an early loading dose
All patients enrolled have been high risk for ACS (TIMI > 4, positive markers, ECG changes)
Guidelines recommend 300mg plavix loading dose in ED if high risk ACS, or suspected ACS with contraindications to ASA
Best to hold if going to CABG, but studies are inconclusive for increased risk of major bleeding
Benefit of therapy outweighs likelihood of going to CABG in most cases
![Page 68: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/68.jpg)
Should we give this patient (NSTEMI) UFH or LMWH? What if they are over 75 years of
age? Or have renal failure? Or have a STEMI?
![Page 69: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/69.jpg)
Several studies have evaluated the role of heparin in STEMI and UA/NSTEMI and as an adjunct to revascularization
Although the evidence for heparin is weak (Cochrane review found only decreased risk of MI and similar risk of mortality or revascularization), it is the standard of care for ACS
In the last 10 years, many trials have tried to answer the question of which heparin to use, beginning with ESSENCE
ESSENCE demonstrated a benefit to enoxaparin over UFH in over 3000 patients with high likelihood ACS in reducing recurrent ischemic events, which was offset by an increase in the risk of minor bleeding
![Page 70: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/70.jpg)
Compared UFH with enoxaparin for over 10,000 NSTEMI patients who were to be treated with an early invasive strategy
Patients with a Cr clearance of <30 mL/min were excluded
30 day composite end point of death or MI Primary efficacy endpoint failed to show superiority
of enoxaparin, although noninferiority criteria were satisfied
There was excess bleeding (not clinically significant) in the enoxaparin group, some of which was attributable to crossover from one to the other
Patients who received only enoxaparin (not intention to treat) had better outcomes at 6 months; at 12 months mortality between the groups was similar
![Page 71: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/71.jpg)
To assess the effects of LMWH compared to UFH for ACS (UA/NSTEMI)
7 studies involving over 10,000 people No difference in overall mortality LMWH showed reduced recurrence of MI and
the need for revascularization procedures No difference in recurrent angina, major
bleeds, or minor bleeds; there was a decrease in the incidence of HIT
125 patients have to be treated with LMWH to prevent 1 MI, and 50 have to be treated to prevent 1 revascularization procedure
Cochrane Database of Systematic Reviews 2003
![Page 72: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/72.jpg)
The ExTRACT-TIMI 25 trial (2006) was an international double blind comparison of enoxaparin vs UFH in over 20,000 patients with STEMI for whom lytics were planned
Dosing regimens were altered for those over 75 and those with reduced renal function
Primary endpoint of death or non-fatal MI occurred in 12% of those with UFH and 9.9% of those with LMWH; there was a small increase in major bleeding in the LMWH group, but not ICH (NNT = 48)
Among patients who underwent PCI within 30 days, the primary endpoint occurred in 10.7% of those receiving LMWH and 13.8% of those receiving UFH
![Page 73: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/73.jpg)
A recent meta-analysis of UFH vs enoxaparin in over 49,000 patients across the ACS spectrum
Primary end point was death, MI, or major bleeding at 30 days
Death or MI was significantly reduced by enoxaparin (9.8% vs 11.4%)
Major bleeding was significantly higher with enoxaparin (4.3% vs 3.4%)
Net clinical end point was significantly lower with enoxaparin (12.5% vs 13.5%); ie. Increase in major bleeding was offset by decrease in death or MI
The net clinical endpoint was significant among STEMI trials but not NSTEACS trials, although there was a significant reduction in death or MI among NSTEACS
![Page 74: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/74.jpg)
![Page 75: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/75.jpg)
Heparin and enoxaparin continue to be I-A level recommendations for UA/NSTEMI, whether the patient is treated with an early invasive strategy or a selectively invasive strategy
Enoxaparin is now the recommended treatment for patients with STEMI receiving lytics (superior efficacy, no increased risk of ICH)
There is not enough data to make a recommendation for patients undergoing primary PCI, however that is the standard of practice here
New recommendations for dosing from the ExTRACT trial 30 mg IV bolus followed by 1 mg/kg Q 12 h If older than 75, omit bolus and administer 0.75 mg/kg Q
12h If Cr Clearance < 30 mL/min, change to Q 24 hours dosing
![Page 76: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/76.jpg)
Should we give this patient (or all patients with ACS) beta blockers?
![Page 77: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/77.jpg)
In the first few hours of onset of STEMI, beta-blockers may diminish myocardial oxygen demand, heart rate, BP, and myocardial contractility, augmenting perfusion to the ischemic myocardium by prolonging diastole
Large early trials (ISIS-2, TIMI-II) suggested a benefit of IV beta-blockers, particularly on recurrent MI and possibly on mortality
However, data from the recent COMMIT trial challenges these findings
![Page 78: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/78.jpg)
Randomized over 45,000 patients within 24 hours of symptoms onset to receive up to three 5 mg doses of IV metoprolol within 15 minutes, followed by 60 mg PO Q 6 h
Primary outcome was all-cause mortality or composite of death, MI, cardiac arrest
Patients undergoing primary PCI excluded No improvement in primary outcome For every 1000 patients treated, there were 5 fewer
reinfarctions and 5 fewer episodes of VF at the expense of 11 additional episodes of cardiogenic shock
This was observed within the first 48 hours of treatment, in close temporal proximity to the IV treatment; reductions in MI and arrythmia occurred later
Relative increased risk of cardiogenic shock was 30%, and were higher in patients > 70, SBP <120, HR > 110 , Killip Class >I
![Page 79: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/79.jpg)
Guidelines similar for STEMI and NSTEACS IV beta-blockers should only be considered ED
therapy in patients with hypertension +/- tachycardia, or in patients who have pain unrelieved by nitrates
Otherwise, oral beta-blockade therapy is recommended to be initiated within the first 24 hours
Contraindications to beta-blockers: Signs of heart failure of low-output state Increased risk of cardiogenic shock (age >70, SBP <120,
HR >110 or <60) Heart block (first through third degree) Reactive airway disease
![Page 80: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/80.jpg)
54 y/o male with known CAD presents to the ED with 45 minutes of CP radiating to left arm
Feels SOB, slightly diaphoretic BP 155/82, HR 110, RR 22, SpO2 96% Exam otherwise normal
![Page 81: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/81.jpg)
![Page 82: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/82.jpg)
The cath lab has an unstable crashing patient on the table, and don’t think they can get to your patient for another hour
How do you want to manage this patient?
![Page 83: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/83.jpg)
Expeditious restoration of flow in the obstructed artery is a key determinant of both short and long term outcomes, and is associated with improved survival
This effect is seen regardless of which method of reperfusion is chosen
Time from onset of symptoms is an important predictor of outcome
Fibrinolytics can dramatically reduce mortality if given within the first 2 hours from onset of symptoms; in some centres, pre-hospital fibrinolysis reduces treatment delays by 1 hour and reduces mortality by 17%
For PCI, time from symptoms onset to balloom inflation is significantly correlated with 1-year mortality; the RR equals 1.08 for each 30 minute delay
![Page 84: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/84.jpg)
It is well established based on large controlled clinical trials that lytics provides a survival benefit
An overview of 9 trials of fibrinolytic therapy vs controls demonstrated a highly significant 18% risk reduction in 35-day mortality (9.6% for lytics vs 11.5% for controls), which corresponds to a reduction of 18 deaths per 1000 treated (NNT 52) when data from all groups are pooled (ICH risk 1% for tPA)
There is a decline of 1.6 lives per 1000 patients treated for every 1-hour delay
In patients with STD, the was an increased risk of mortality (7.4% vs 4.9% for conservative Tx)
![Page 85: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/85.jpg)
![Page 86: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/86.jpg)
![Page 87: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/87.jpg)
The mortality benefit of fibrinolytic therapy diminishes as duration from symptom onset increases: 0-1 h: 65 lives saved
per 1000 pts Rx 1-2 h: 37 lives saved 2-3 h: 26 lives saved 2-6 h: 29 lives saved
Effect of fibrinolysis on 35 d mortality
Boersma et al. Lancet 1996;348:771
![Page 88: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/88.jpg)
Adjusted probability of death or cerebral bleeding in patients >75
At 30 days, this was 23% vs 32% and at 1 year 26% vs 36% for those treated with lytics vs not
At 1 year, this is a RRR of 13% and an ARR of 4% (NNT = 25)
![Page 89: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/89.jpg)
![Page 90: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/90.jpg)
Class I In the absence of contraindications, fibrinolytic
therapy should be administered to STEMI patients with symptoms onset within the prior 12 hours and STE > 0.1 mV in at least 2 contiguous precordial leads or 2 adjacent limb leads
In the absence of contraindications, fibrinolytics should be administered to STEMI patients with symptom onset in the prior 12 hours and a new or presumed new LBBB
The 9 studies analyzed in the Fibrinolytic Therapy Trialists Collaborative Group defined STE as > 1mm STE in 2 or more limb leads and > 2mm STE in 2 or more precordial leads
![Page 91: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/91.jpg)
Absolute Any prior ICH Known structural
cerebral vascular lesion Brain tumour Ischemic CVA within
the last 3 months (EXCEPT within 3 hours)
Suspected aortic dissection
Active bleeding diathesis (not menses)
Signigicant head or facial trauma within 3 months
Relative Hx of chronic, severe,
poorly controlled HTN SBP > 180, DBP > 110 Prior ischemic CVA > 3
months, dementia, or known intracranial pathology
Trauma, CPR (>10 min), or major surgery within 3 wk
Recent internal bleeding (2-4 weeks)
Pregnancy Active PUD Current use of
anticoagulents
![Page 92: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/92.jpg)
Do you give this patient lytics, or do you wait an hour for the cath lab?
![Page 93: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/93.jpg)
PCI is successful in achieving TIMI 3 flow in 70-90% of patients
Has been compared to fibrinolytics in 22 randomized clinical trials, plus the SHOCK trial
These studies demonstrated that PCI-treated patients have lower short-term mortality rates (5% vs 7%), less reinfarction (3% vs 7%), and less hemorrhagic stroke (0.05% vs 1%) than those treated with lytics; combine end point was better overall for PCI (8% vs 14%)
Much of the superiority of primary PCI is driven by a reduction in the rate of non-fatal MI
![Page 94: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/94.jpg)
![Page 95: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/95.jpg)
The mean time delay for primary PCI in the RCTs was 40 minutes
However, there is concern that routine policies of primary PCI may result in unacceptable delays to treatment
An analysis of the RCTs that compares PCI to lytics suggests that the mortality benefit with PCI exists only if treatment is delayed by no more than 60 minutes
In PRAGUE-2, in the subset of patients presenting within 3 hours of symptoms, there was no mortality benefit for PCI (although PCI was better overall)
In CAPTIM, patients treated within 2 hours of symptom onset had better outcomes with pre-hospital tPA vs transfer for primary PCI (trend toward reduced mortality)
Both studies showed that PCI was better than lytics if symptom duration was greater than 2-3 hours
![Page 96: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/96.jpg)
![Page 97: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/97.jpg)
Class I If immediately available, primary PCI should
be performed as quickly as possible with a goal of medical contact to balloon time of 90 minutes (vs goal door to needle time of 30 minutes)
If symptoms duration is within 3 hours and door to needle time is: Within 1 hour – primary PCI preferred > 1 hour – fibrinolytic therapy is preferred
If symptom duration time is > 3 hours, primary PCI is generally preferred
![Page 98: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/98.jpg)
Just as you’re about to order TNK, the patient suddenly becomes hypotensive and appears to be in respiratory distress
BP is 74/50, HR 125,SpO2 86%, CXR demonstrates pulmonary edema
You cautiously intubate(!) and line this patient, judiciously provide fluids, and start him on dopamine
Will you give TNK now?
![Page 99: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/99.jpg)
302 patients with STEMI and LV dysfunction randomized to emergency revascularization within 6 hours (angioplasty, CABG, +/- IABP) or medical stabilization (+/- lytics, +/- IABP)
There was a non-significant 9% ARR in 30 day mortality with revascularization overall
The benefit was larger and statistically significant for those < 75 (subgroup analysis)
The overall mortality was significantly reduced at 6 months in patients who underwent revascularization
![Page 100: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/100.jpg)
![Page 101: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/101.jpg)
Class I Primary PCI should be performed for patients
<75 with STEMI or LBBB who develop shock within 36 hours of MI
Primary PCI should be performed in patients with severe CHF (Killip class 3) and onset of symptoms within 12 hours
Class II Primary PCI should be considered for those
>75 and shock It is reasonable to perform primary PCI for
patients with onset of symptoms within 12-24 hours
![Page 102: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/102.jpg)
Fibrinolysis is generally preferred if Early presentation
(<3 hours) and delay to PCI
PCI not available Delay to invasive
strategy [Door to balloon] –
[Door to needle] >1hr Presentation to balloon
time > 90 minutes
PCI generally preferred if Skilled PCI lab
available with surgical back-up
High-risk patient Cardiogenic shock Killip class 3 or
greater Contraindications to
fibrinolysis Late presentation Diagnosis in doubt
![Page 103: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/103.jpg)
You are the REP on call and receive a call from Golden about a 57 y/o male with an anterior STEMI who “failed TNK”
His onset of symptoms was 10:00, and he was treated with fibrinolytics at 14:45 (within 30 minutes of presentation to hospital)
It is now 1600h and the patient is having ongoing symptoms with no resolution of his STE on the ECG
What is the definition of “failed fibrinolysis” and does this patient require “Rescue PCI”?
![Page 104: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/104.jpg)
Fibrinolysis is successful in restoring TIMI 2/3 flow in 50-85% of patients
If ST segment elevation in the lead showing the greatest degree of STE has not resolved by at least 50% 90 minutes after administration of a lytic, fibrinolysis is considered to have failed
Resue (salvage) PCI is defined as PCI within 12 hours after failed fibrinolysis for patients with continuing or recurrent ischemia
The RESCUE trial demonstrated a reduction in in-hospital mortality in patients with anterior STEMI who failed fibrinolytic therapy, when PCI was performed within 8 hours of symptoms
![Page 105: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/105.jpg)
Rescue PCI after fibrinolytic therapy is recommended in the following circumstances: Patients in cardiogenic shock < 75 Patients with severe heart failure Patients with hemodynamically compromising
ventricular dysrhythmias It is reasonable to perform resuce PCI if:
Patients in cardiogenic shock >75 Patients with persistent symptoms, or
hemodynamic or electrical instability Patients in whom lytics have failed and a moderate
to large area of myocardium is at risk
![Page 106: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/106.jpg)
What are the complications of an MI?
![Page 107: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/107.jpg)
CHF Cardiogenic shock Arrythmias Heart blocks Reperfusion arrythmias Acute MR Ventricular wall rupture and tamponade VSD LV aneurysm Thromboembolism Post-MI pericarditis
![Page 108: Yael Moussadji Aug 21, 2008. Diagnosis of ACS in the ED Risk Stratification Cardiac markers ECG Risk Scores Management UA/NSTEMI STEMI.](https://reader031.fdocuments.net/reader031/viewer/2022013004/56649f385503460f94c54ec6/html5/thumbnails/108.jpg)
THE END!